Investigating how bromodomains affect breast cancer treatment responses
Project 2: Bromodomains as Epigenetic Modulators of Endocrine Responsiveness in ER+ Breast Cancer
This study is looking at how certain proteins affect the success of anti-estrogen treatments for the most common type of breast cancer, with the goal of finding better ways to help patients who struggle with treatment resistance.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-11074068 on NIH RePORTER |
What this research studies
This research focuses on understanding how bromodomain proteins influence the effectiveness of anti-estrogen therapies in estrogen receptor-positive breast cancer, which is the most common type of breast cancer. The study aims to uncover the molecular mechanisms behind therapy resistance, which often leads to treatment failure and disease progression. By examining the role of histone acetylation and bromodomain interactions, researchers hope to identify new strategies to enhance treatment responses and overcome resistance. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with estrogen receptor-positive breast cancer who are undergoing or have undergone anti-estrogen therapy.
Not a fit: Patients with other subtypes of breast cancer or those who are not receiving anti-estrogen therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with estrogen receptor-positive breast cancer, potentially reducing the risk of therapy resistance.
How similar studies have performed: Previous research has shown promising results in targeting bromodomains as a therapeutic strategy in cancer, indicating potential for success in this approach.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Frietze, Seth E — University of Vermont & St Agric College
- Study coordinator: Frietze, Seth E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.